Pre-made Cevostamab benchmark antibody ( Bispecific mAb, anti-FCRL5;CD3 therapeutic antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-103
Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-I|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Multiple myeloma|